MK-677

What it is

MK-677 (ibutamoren) is an orally bioavailable small-molecule ghrelin receptor agonist developed by Merck in the 1990s. Despite often being grouped with peptide GH secretagogues, MK-677 is technically not a peptide — it is a synthetic small molecule that mimics ghrelin’s effects on the GH-releasing pathway.

MK-677 was studied by Merck in the 1990s and 2000s for GH deficiency, frailty in elderly populations, and other indications. The development program was eventually discontinued. The compound was later licensed to other companies for development in pediatric GH deficiency, but has not received FDA approval for any indication. MK-677 is not FDA-approved for any use in the United States.

Mechanism of action

Proposed mechanisms come from laboratory, animal, and early human research. MK-677 acts as a ghrelin receptor (GHS-R1a) agonist:

• GH and IGF-1 elevation: in human pharmacology studies, MK-677 was associated with sustained increases in GH and IGF-1 levels
• Appetite stimulation: ghrelin receptor activation has been associated with increased appetite
• Sleep effects: changes in sleep architecture have been reported in small studies
• Long half-life: approximately 24 hours

Clinical evidence

MK-677 was evaluated in clinical trials during the Merck development program:

• Studies reported increases in GH and IGF-1 levels
• Small studies in elderly participants have been published; benefit in people has not been established
• Studies in participants with obesity reported metabolic changes alongside increased appetite
• A trial in older adults recovering from hip fracture reported mixed functional outcomes

Well-controlled human trials establishing effectiveness and safety for any use are lacking, and the compound has not been approved.

Why we don’t prescribe it at The Tide

The Tide does not prescribe or offer MK-677. Concerns noted in the research literature include:

• Continuous signaling: MK-677 produces continuous rather than pulsatile GH/IGF-1 elevation, and the long-term consequences of this pattern are unknown
• Appetite stimulation: increased appetite and weight gain have been reported
• Insulin resistance: sustained GH elevation has been associated with reduced insulin sensitivity and higher blood sugar
• Water retention and joint discomfort: reported in clinical studies
• Not technically a peptide: MK-677 is a small molecule

Side effects and contraindications

Human safety has not been established for long-term use. Reported effects include increased appetite, fluid retention, joint discomfort, fatigue, and reduced insulin sensitivity, and sustained GH/IGF-1 elevation raises concerns about growth-promoting signaling in people with cancer. Products sold outside regulated channels (for example, as “research chemicals”) may vary in purity, dose, and identity.